Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM)

Karthaus, Meinolf; Metzner, D.; Maher, G.; Plahl, A.; Wert, N.

doi:10.1200/jco.2004.22.90140.7201

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the median survival for single-agent PEM (including a mixed chemonaïve/previously treated population) was 10.3 months (although patients in the PEM group had poorer prognostic characteristics than other groups; see below). Also, in an EU study conducted in peritoneal or mixed peritoneal and pleural mesothelioma patients (including both chemo-naïve/previously treated patients) with PEM and a platinum agent, response rates (PM patients = 36%, PM and pleural patients = 40%) were higher than the current study [28].…”

Section: Discussioncontrasting

confidence: 81%

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Cartenì¹,

Manegold²,

García³

et al. 2009

Lung Cancer

117

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 81%

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Cartenì¹,

Manegold²,

García³

et al. 2009

Lung Cancer

117

View full text Add to dashboard Cite

“…Cures are evasive and most patients die within 2 years of diagnosis, though there are exceptions. Mesothelioma that develops in carriers of BAP1 germline mutations seem to be associated with better prognosis, with a median survival of 5–10 years. ,− Chemotherapy with cisplatin and pemetrexed has been the backbone of palliative therapy since 2004. , However, there are encouraging indications that this “old” standard for first-line therapy of MM will soon be replaced by the nivolumab/ipilimumab (immunotherapy) combination. Nivolumab + ipilimumab showed a 4 months survival advantage in a head to head comparison with cisplatin + pemetrexed in a large (605 pts) phase III study …”

Section: Asbestos-related Diseasementioning

confidence: 99%

“…43,52−54 Chemotherapy with cisplatin and pemetrexed has been the backbone of palliative therapy since 2004. 55,56 However, there are encouraging indications that this "old" standard for firstline therapy of MM will soon be replaced by the nivolumab/ ipilimumab (immunotherapy) combination. Nivolumab + ipilimumab showed a 4 months survival advantage in a head to head comparison with cisplatin + pemetrexed in a large (605 pts) phase III study.…”

Section: ■ Asbestos-related Diseasementioning

confidence: 99%

Asbestos and Zeolites: from A to Z via a Common Ion

Reid

Klebe

Zandwijk

et al. 2021

Chem. Res. Toxicol.

View full text Add to dashboard Cite

Asbestos and zeolites are silicate-based minerals, linked inextricably via paradoxical similarities and differences which have emanated from different geological epochs. Both have been employed in the service of humanity through millennia: asbestos, for its “inextinguishable” quality of being an insulator against heat and fire; zeolite, a “boiling stone” with its volcanic and marine sedimentary rock origins, for its propensity to adsorb water and remove metals and toxins. Serious adverse health effects observed in asbestos miners as long ago as the 1st Century AD did not halt the rising popularity of asbestos. As the miracle material of the 1900s, asbestos production and consumption exploded, culminating in its ubiquity in ships, vehicles, homes, commercial buildings, and over 3000 different industrial and household products. Through the 1940s and 1950s, epidemiological studies concluded that asbestos was a likely cause of asbestosis, lung cancer, and malignant mesothelioma, and it is now banned in many but far from all countries. The long latency between exposure to asbestos and the occurrence of cancer has obscured the deadly consequences of asbestos exposure for centuries. Even today, a considerable part of the world population is insufficiently aware of the dangers of asbestos, and millions of tons of this carcinogen continue to be mined and used worldwide. Zeolites, both natural and synthetic, are microporous aluminosilicate minerals commonly used in a myriad of processes, in the petrochemical industry, in domestic appliances and cleaning agents, as commercial adsorbents and exchangers for toxins and pollutants, and as catalysts. Zeolites are found in agriculture, veterinary science, and human health. More recently, new materials such as carbon nanotubes are being employed in materials requiring durability and thermal and electrical conductivity, yet nanotubes are now joining the ranks of more established particulates such as asbestos and silica, in causing human disease. In this review, we compare and contrast the similarities and differences of these two groups of silicate minerals and their waxing and waning use in the employ of humanity.

show abstract

“…1 zu entnehmen. Die Daten der deutschen Arbeitsgruppe um Karthaus et al und die Daten des EAP (Expanded Access Program) postulieren bei peritonealen DMM für eine Kombinationstherapie mit Pemetrexed und Cisplatin ähnliche Ansprechraten [20,21]. Andere Agenzien, die in der Therapie des Mesothelioms eingesetzt werden, sind das Vinka-Alkaloid Vinorelbine und das Pyrimidin-Analogon Gemcitabine, letzteres in Kombination mit Cisplatin oder Carboplatin mit recht guten Ergebnissen [17].…”

unclassified

Diffuse maligne peritoneale Mesotheliome - Eine ungewöhnliche Differenzialdiagnose bei Adenokarzinomen des Ovars

Thill¹,

Braun²,

Jackisch³

2007

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Einleitung ! Diffuse maligne Mesotheliome (DMM) sind ungewöhnliche Tumoren mit einer Inzidenz von etwa 1 : 1000 000 und von 2500 Fällen pro Jahr in den USA [1]. Die Inzidenz maligner Mesotheliome nimmt aufgrund der weit verbreiteten Asbestexposition weltweit zu. Aufgrund der langen Latenzzeit einer Asbestexposition wird der Höhe-punkt in vielen Entwicklungsländern wahrscheinlich erst innerhalb der nächsten 20 Jahre erreicht werden [2]. Peritoneale DMM werden somit als Differenzialdiagnose mehr und mehr in den Fokus des Gynäkoonkologen kommen müssen. Ungefähr 50 -70% sind mit einer AsbestExposition vergesellschaftet. In einigen Gegenden der Türkei sind Mesotheliome endemisch, da dort ein weißer Tuffstein, in dem Erionit -ein asbestähnliches Mineral -enthalten ist, gerne für den Bau von Häusern verwendet wird. Ein weiterer Risikofaktor ist eine aufgrund einer anderen malignen Erkrankung durchgeführte Radiotherapie [3]. Zusammenfassung ! Diffuse maligne Mesotheliome sind ungewöhnli-che, aggressive Tumoren, die von der Oberfläche der Serosa in Körperhöhlen ausgehen. Die Inzidenz dieser Erkrankung nimmt aufgrund der weit verbreiteten Asbestexposition, die häufigste Ursache für die Entstehung von malignen Mesotheliomen, weltweit stetig zu. Etwa 85 % der malignen Mesotheliome entstehen in der Pleura, nur 9% im Peritoneum, noch seltener ist das Auftreten in Perikard und Tunica vaginalis testis. Wir berichten von dem Fall einer 51-jährigen türki-schen Patientin, die wegen Bauchschmerzen und Aszites mit der Diagnose eines primären Ovarialkarzinoms mit peritonealer Aussaat einer Explorativlaparotomie unterzogen wurde. Postoperativ wurde jedoch ein diffuses malignes epitheliales Mesotheliom des Peritoneum bestätigt. Im Anschluss an die Operation wurde eine Therapie mit Pemetrexed und Cisplatin eingeleitet. Hatte die Therapie früher einen nur palliativen Charakter, so zeigen zuletzt veröffentlichte Studien einen Benefit für kleine Patientengruppen, die mit einer zytoreduktiven Chirurgie mit hyperthermer Peritonealperfusion behandelt wurden. Die Prognose ist unbehandelt schlecht und das mediane Überleben nur etwa ein Jahr.Abstract ! Diffuse malignant mesotheliomas are uncommon aggressive tumors of serosal surfaces of body cavities. The incidence of these tumors is increasing worldwide, probably as a result of the widespread exposure to asbestos, a factor with which these tumors are associated. About 85 % of mesotheliomas arise in the pleura, 9% in the peritoneum, a small percentage in the pericardium or tunica vaginalis testis. We report the case of a 51-year-old woman with ascites and abdominal pain who underwent laparotomy with the diagnosis of primary ovarian cancer with intraperitoneal spread. After surgery the diagnosis of a malignant peritoneal mesothelioma was considered. The patient is now undergoing treatment with systemic chemotherapy consiting of pemetrexed and cisplatin. Intensive multimodal approaches that combine cytoreductive surgery with intraperitoneal hyperthermic perfusion have been evaluated in recent studi...

show abstract

Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM)

Cited by 5 publications

References 0 publications

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Asbestos and Zeolites: from A to Z via a Common Ion

Diffuse maligne peritoneale Mesotheliome - Eine ungewöhnliche Differenzialdiagnose bei Adenokarzinomen des Ovars

Contact Info

Product

Resources

About